GSK’s Blenrep Set For Comeback After Overall Survival Win

Blenrep improved overall survival in the DREAMM-7 study in multiple myeloma patients compared with Darzalex, confirming the antibody-drug conjugate’s likely return to the market and potential blockbuster status.